Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
what he described as “extraordinary” early survival results for the company's lead program, atebimetinib, in first-line pancreatic cancer, and outlined multiple upcoming clinical and regulatory milestones across pancreatic and lung cancer. Phase II pancreatic cancer survival update and near-term catalysts Zeskind said the company reported in January a 12-month overall survival (OS) rate of 64% in first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, with median OS not yet reached at the time of that cutoff. He said the dataset had a 13.4-month median follow-up and included 34 patients, exceeding the original enrollment goal of 30. ? 3 Surprising S&P 500 Outperformers of 2026 He also highlighted a cross-trial comparison against the pivotal MPACT study for gemcitabine/nab-paclitaxel (GNP), which he cited as having shown 35% 12-month OS. Zeskind emphasized that Immuneering's survival curves “separate early” and remain separated at six,
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering (IMRX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "MarketBeat
- Immuneering to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and SurvivalGlobeNewswire
- Immuneering (IMRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 3/17/26 - Form 4
- 3/6/26 - Form 10-K
- 3/6/26 - Form 8-K
- IMRX's page on the SEC website